April 19, 2016
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of new immuno-oncology therapies. It has recently announced results of three preclinical studies of the Company’s lead oral checkpoint inhibitor, CPI-444. The studies demonstrated that CPI-444, a potent and selective inhibitor of the adenosine A2A receptor, was effective in stimulating various immune cells that generated anti-tumor immunity, suppressed tumor growth, and delayed tumor progression in animal models of cancer. The data were presented in 2016 Annual Meeting of American Association for Cancer Research (AACR) in New Orleans.
Richard A. Miller, M.D., an oncologist and co-founder, president and chief executive officer of Corvus, said: “These preclinical studies demonstrate that CPI-444 enhances the immune response to various tumors in animal models of melanoma, breast and colon cancer. Enhancement of T-cell function was also corroborated with adoptively transferred T-cells and with tumor vaccines, indicating that this agent may have broad applications in immuno-oncology. These studies support our commitment to advancing the clinical development of CPI-444 as an immuno-oncology therapy for many types of cancer. Based on these study findings and others, we have begun enrolling patients in a Phase 1/1b clinical trial to evaluate the safety, tolerability and preliminary efficacy of CPI-444 as a single agent and in combination with an anti-PD-L1 in patients with solid tumors.”